Baker BROS. Advisors LP Buys Shares of 2,822,727 BioCryst Pharmaceuticals, Inc. $BCRX

Baker BROS. Advisors LP bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,822,727 shares of the biotechnology company’s stock, valued at approximately $22,017,000. Baker BROS. Advisors LP owned approximately 1.34% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Larson Financial Group LLC boosted its position in BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares during the last quarter. Focus Partners Wealth acquired a new stake in BioCryst Pharmaceuticals during the third quarter valued at $77,000. Mirae Asset Global Investments Co. Ltd. boosted its position in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at $81,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in BioCryst Pharmaceuticals during the third quarter valued at $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $8.95 on Thursday. The business has a 50 day moving average price of $8.92 and a 200 day moving average price of $8.16. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $10.32. The firm has a market cap of $2.27 billion, a P/E ratio of -5.03 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same quarter last year, the business earned $0.20 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on BCRX shares. Needham & Company LLC reduced their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Wedbush cut their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Citizens Jmp raised their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $20.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.